
Genentech’s Fenebrutinib Shows Significant Efficacy in Relapsing Multiple Sclerosis
Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than…












